Mantle Cell Lymphoma | Tumor

CURE’s mantle cell lymphoma (MCL) page features the latest cancer news and updates on mantle cell lymphoma Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in mantle cell lymphoma.

Patients With Mantle Cell Lymphoma Continue to Respond to Tecartus Three Years Later

June 22nd 2022, 1:00pm


Long-term follow-up shows that the CAR-T cell therapy Tecartus continues to elicit durable responses in patients with relapsed/refractory mantle cell lymphoma.

‘A New Benchmark’ Treatment Option for Older Patients with Mantle Cell Lymphoma

June 3rd 2022, 7:36pm


Adding Imbruvica to a standard-of-care chemotherapy-immunotherapy treatment regimen was associated with a significant improvement in survival in older patients with newly diagnosed mantle cell lymphoma.

Trial Launches to Study a New Drug for B-Cell Malignancies

May 20th 2022, 7:00pm


NX-5948 may be able to pass through the blood-brain barrier in patients with B-cell malignancies, potentially making it a promising option for patients with disease in their central nervous system.

'Death Doulas' Help Patients With Cancer Face Their End of Life With Courage and Meaning

May 18th 2022, 7:00pm


Dying does not have the be scary, and there are resources available to help patients and their loved ones, explained an expert.

Two-Drug Combo Elicits Similar Outcomes to Standard of Care in Young Patients With Non-Hodgkin Lymphoma

May 11th 2022, 9:00pm


The use of bendamustine and Rituxan plus autologous stem cell transplantation and maintenance Rituxan resulted in similar outcomes to other Rituxan-based regimens that are currently the standard of care for young patients with mantle cell lymphoma, a type of non-Hodgkin lymphoma, who are eligible for transplant.

Pharma Company Stops Patient Enrollment in Ewing Sarcoma Trial to Prioritize Development of a Blood Cancer Drug

April 15th 2022, 9:00pm


The plan, according to the San Diego-based pharmaceutical company, is to launch a phase 3 trial to analyze the safety and efficacy of a novel drug in mantle cell lymphoma in the second half of 2022.

Now That Telemedicine is a Mainstay in Cancer Care, One Expert Notes When Patients Should Opt for Virtual Appointments

April 6th 2022, 7:00pm


The COVID-19 pandemic brought on a huge surge in the use of telemedicine for cancer care, but now as the pandemic is slowing down, an expert said that there are certain times when telemedicine will do, while other situations warrant an in-person visit with the doctor.

CAR-T Cell Therapies Offer ‘An Opportunity for Majority of Patients’ With Lymphoma to Be Treated

March 14th 2022, 3:00pm


Unlike stem cell transplant, which has strict eligibility criteria, the majority of patients with blood cancer may be able to receive CAR-T cell therapy, regardless of other comorbidities, explained an expert.

CAR-T Cell Therapies Provide Patients With Mantle Cell and Follicular Lymphoma a ‘One and Done’ Treatment Option, Expert Says

March 2nd 2022, 10:00pm


CAR-T cell therapies offer patients with lymphoma a chance for long-term remission, but none have yet to receive a greenlight from the FDA as a first line of treatment.

Addition of Ofatumumab to Aggressive Chemotherapy Regimen Yields High Response Rates in Newly Diagnosed Mantle Cell Lymphoma

March 2nd 2022, 2:00pm


Treatment with ofatumumab plus an aggressive regimen of chemotherapies resulted in a response rate of more than 80% in patients with newly diagnosed mantle cell lymphoma.